Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

Bullboard Posts

Post by cpilgrimon Apr 30, 2020 9:30pm

206 Views

Post# 30974325

Warrant Question

If the special warrant price is 40c, and the strike price/exercise price is 60c, that makes the cost of each share for Mackie $1. That's why they stipulate that if it's trading over $1 for more than 10 days, they'll put a time limit on exercising the warrants. Otherwise it would be like selling their shares for less than they're trading.

If I'm correct, this only makes sense if AGN/Mackie sees a $1 SP coming within the next 2 years or sooner (the time limitation of exercising the warrants). If they didn't expect it sooner, there wouldn't be a stipulation to accelerate the exercise deadline.

I'm not a professional. DYODD.

Bullboard Posts

StockTalk | Cannabis Report: New CEO, new dispensaries, new strains